 - Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis, the uncertain risk of this regimen on tumor bleeding, and because these patients often develop progressive neurological dysfunction that would confound the evaluation of neurologic and other adverse events. Patients with primary malignancies known to metastasize to the brain such as lung cancer, breast cancer, renal cell cancer, , sarcoma, carcinoma of unknown primary, melanoma, and head and neck cancers or patients with symptoms of brain metastases should have a brain MRI within 28 days of enrollment to confirm the absence of CNS metastases. Contrast CT is acceptable for patients who are unable to undergo a brain MRI. 